Risk Factors and Machine Learning Model for Beta-Lactam Drugs Related Acute Kidney Injury

Acute Kidney Injury Clinical Trial

Official title:

Analysis of Risk Factors of Beta-Lactam Drugs Related Acute Kidney Injury in Hospitalized Patients and Developments of Machine Learning Model

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05533606
• Other study ID #: LCYY-LX-20220103
• Status: Completed
• Start date: July 1, 2022
• Est. completion date: June 30, 2023

Study information

• Verified date: November 2023
• Source: Qianfoshan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Acute kidney injury (AKI), also known as acute kidney failure (ARF), is a common and complex kidney disease in clinic and an important factor related to poor prognosis of patients in clinic. In the present study, a single-center retrospective study was conducted in our center. The clinical data of hospitalized patients received β-Lactam drugs from January 2018 to December 2020 was retrospectively analyzed. The multiple logistic regression analysis suggested that complicated with hypertension, anemia, pneumonia, shock, sepsis, heart failure, combined use of proton pump inhibitors (PPI), angiotensin-converting enzyme inhibitor (ACEI), angiotensin Ⅱ receptor antagonist (ARB) were independent risk factors for AKI related to β-Lactam drugs. In clinical practice, patients with acute kidney injury risk factors should be closely monitored for changes in their blood creatinine and urine output to avoid acute kidney injury. For patients who have suffered from acute kidney injury, the cause should be removed in time and corresponding symptomatic treatment should be given.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19000
• Est. completion date: June 30, 2023
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• All inpatients who used ß-lactam drugs during hospitalization

• Hospital stay = 48h

• Age =18 years

• There are two or more blood creatinine tests during hospitalization

Exclusion Criteria:

• Hospital stay < 48h

• Age <18 years

• Glomerular filtration rate (GFR)< 30ml/min/1.73m2 within 48 hours after admission

• AKI was diagnosed on admission

• Less than two Scr test results during hospitalization

• The Scr values were always lower than 40 µmol/L during hospitalization

• Cases with incomplete medical history information

Related Conditions & MeSH terms

• Acute Kidney Injury
• Wounds and Injuries

Intervention

Drug:
• Beta-Lactam Drugs
During hospitalization,patients used Beta-Lactam drugs.

Locations

Country	Name	City	State
China	Xiao Li,MD	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Qianfoshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidence of acute kidney injury in hospitalized patients treated with ß-lactam drugs	To analyze the incidence of acute kidney injury in hospitalized patients after using ß-lactam drugs and to build a prediction model.	Through study completion,up to half a year.